Citigroup analyst Fatima Boolani maintains Check Point Software (NASDAQ:CHKP) with a Sell and lowers the price target from $122 to $120.
Where Immunovant Stands With Analysts
Immunovant (NASDAQ:IMVT) has observed the following analyst ratings within the last quarter: